Search

Your search keyword '"Filippatos, Gerasimos"' showing total 4,182 results
Start Over Author "Filippatos, Gerasimos"
4,182 results on '"Filippatos, Gerasimos"'

1. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

Author

Čelutkienė, Jelena, Čerlinskaitė-Bajorė, Kamilė, Cotter, Gad, Edwards, Christopher, Adamo, Marianna, Arrigo, Mattia, Barros, Marianela, Biegus, Jan, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Léopold, Valentine, Deniau, Benjamin, Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Lam, Carolyn S. P., Voors, Adriaan A., Mebazaa, Alexandre, and Davison, Beth

Published
2024
Full Text
View/download PDF

2. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

Author

Vaduganathan, Muthiah, Filippatos, Gerasimos, Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Henderson, Alasdair, Brinker, Meike, Kolkhof, Peter, Schloemer, Patrick, Lay-Flurrie, James, Viswanathan, Prabhakar, Lam, Carolyn S. P., Senni, Michele, Shah, Sanjiv J., Voors, Adriaan A., Zannad, Faiez, Rossing, Peter, Ruilope, Luis M., Anker, Stefan D., Pitt, Bertram, Agarwal, Rajiv, McMurray, John J. V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

3. Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

Author

Vaduganathan, Muthiah, Filippatos, Gerasimos, Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Henderson, Alasdair, Brinker, Meike, Kolkhof, Peter, Schloemer, Patrick, Lay-Flurrie, James, Viswanathan, Prabhakar, Lam, Carolyn S. P., Senni, Michele, Shah, Sanjiv J., Voors, Adriaan A., Zannad, Faiez, Rossing, Peter, Ruilope, Luis M., Anker, Stefan D., Pitt, Bertram, Agarwal, Rajiv, McMurray, John J. V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

4. Galectin-3, Acute Kidney Injury and Myocardial Damage in Patients With Acute Heart Failure.

Author

Horiuchi, Y, Wettersten, Nicholas, VAN Veldhuisen, Dirk, Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael, Cannon, Chad, Müeller, Gerhard, Birkhahn, Robert, Taub, Pam, Vilke, Gary, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Duff, Stephen, Maisel, Alan, and Murray, Patrick

Subjects
acute heart failure, acute kidney injury, galectin-3, myocardial injury, prognosis, renal tubular damage, Humans, Acute Disease, Acute Kidney Injury, Biomarkers, Cardiomyopathies, Galectin 3, Heart Failure, Kidney, Lipocalin-2, Natriuretic Peptide, Brain, Prognosis, Retrospective Studies, Troponin I
Abstract

BACKGROUND: Galectin-3, a biomarker of inflammation and fibrosis, can be associated with renal and myocardial damage and dysfunction in patients with acute heart failure (AHF). METHODS AND RESULTS: We retrospectively analyzed 790 patients with AHF who were enrolled in the AKINESIS study. During hospitalization, patients with galectin-3 elevation (> 25.9 ng/mL) on admission more commonly had acute kidney injury (assessed by KDIGO criteria), renal tubular damage (peak urine neutrophil gelatinase-associated lipocalin [uNGAL] > 150 ng/dL) and myocardial injury (≥ 20% increase in the peak high-sensitivity cardiac troponin I [hs-cTnI] values compared to admission). They less commonly had ≥ 30% reduction in B-type natriuretic peptide from admission to last measured value. In multivariable linear regression analysis, galectin-3 was negatively associated with estimated glomerular filtration rate and positively associated with uNGAL and hs-cTnI. Higher galectin-3 was associated with renal replacement therapy, inotrope use and mortality during hospitalization. In univariable Cox regression analysis, higher galectin-3 was associated with increased risk for the composite of death or rehospitalization due to HF and death alone at 1 year. After multivariable adjustment, higher galectin-3 levels were associated only with death. CONCLUSIONS: In patients with AHF, higher galectin-3 values were associated with renal dysfunction, renal tubular damage and myocardial injury, and they predicted worse outcomes.

Published
2023

8. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.

Author

Filippatos, Gerasimos, Anker, Stefan, August, Phyllis, Coats, Andrew, Januzzi, James, Mankovsky, Boris, Rossing, Peter, Ruilope, Luis, Pitt, Bertram, Sarafidis, Pantelis, Teerlink, John, Kapelios, Chris, Gebel, Martin, Brinker, Meike, Joseph, Amer, Lage, Andrea, Bakris, George, and Agarwal, Rajiv

Subjects
All-cause mortality, Cardiovascular mortality, Chronic kidney disease, Finerenone, Non-steroidal MRA, Type 2 diabetes, Humans, Middle Aged, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Mineralocorticoid Receptor Antagonists, Renal Insufficiency, Chronic, Heart Failure, Death, Sudden, Cardiac
Abstract

AIMS: Finerenone reduces the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We investigated the causes of mortality in the FIDELITY population. METHODS AND RESULTS: The FIDELITY prespecified pooled data analysis from FIDELIO-DKD and FIGARO-DKD excluded patients with heart failure and reduced ejection fraction. Outcomes included intention-to-treat and prespecified on-treatment analyses of the risk of all-cause and cardiovascular mortality. Of 13 026 patients [mean age, 64.8 years; mean estimated glomerular filtration rate (eGFR), 57.6 mL/min/1.73 m2], 99.8% were on renin-angiotensin system inhibitors. Finerenone reduced the incidence of all-cause and cardiovascular mortality vs. placebo (8.5% vs. 9.4% and 4.9% vs. 5.6%, respectively) and demonstrated significant on-treatment reductions [hazard ratio (HR), 0.82; 95% confidence interval (CI), 0.70-0.96; P = 0.014 and HR, 0.82; 95% CI, 0.67-0.99; P = 0.040, respectively]. Cardiovascular-related mortality was most common, and finerenone lowered the incidence of sudden cardiac death vs. placebo [1.3% (incidence rate 0.44/100 patient-years) vs. 1.8% (0.58/100 patient-years), respectively; HR, 0.75; 95% CI, 0.57-0.996; P = 0.046]. The effects of finerenone on mortality were similar across all Kidney Disease: Improving Global Outcomes risk groups. Event probability with finerenone at 4 years was consistent irrespective of baseline urine albumin-to-creatinine ratio, but seemingly more pronounced in patients with higher baseline eGFR. CONCLUSION: In FIDELITY, finerenone significantly reduced the risk of all-cause and cardiovascular mortality vs. placebo in patients with T2D across a broad spectrum of CKD stages while on treatment, as well as sudden cardiac death in the intention-to-treat population. CLINICAL TRIALS REGISTRATION: FIDELIO-DKD and FIGARO-DKD are registered with ClinicalTrials.gov, numbers NCT02540993 and NCT02545049, respectively (funded by Bayer AG).

Published
2023

9. Implications of worsening renal function before hospitalization for acute heart failure

Author

Wettersten, Nicholas, Duff, Stephen, Horiuchi, Yu, Veldhuisen, Dirk J, Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C, Cannon, Chad M, Müeller, Gerhard A, Birkhahn, Robert, Taub, Pam, Vilke, Gary M, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Maisel, Alan, Murray, Patrick T, and Ix, Joachim H

Subjects
Kidney Disease, Heart Disease, Clinical Research, Cardiovascular, Patient Safety, Renal and urogenital, Humans, Kidney, Creatinine, Acute Disease, Biomarkers, Heart Failure, Hospitalization, Acute heart failure, Acute kidney injury, Cardiorenal syndrome, Cardiorespiratory Medicine and Haematology
Abstract

AimsKidney function changes dynamically during AHF treatment, but risk factors for and consequences of worsening renal function (WRF) at hospital admission are uncertain. We aimed to determine the significance of WRF at admission for acute heart failure (AHF).Methods and resultsWe evaluated a subgroup of 406 patients from The Acute Kidney Injury Neutrophil gelatinase-associated lipocalin Evaluation of Symptomatic heart failure Study (AKINESIS) who had serum creatinine measurements available within 3 months before and at the time of admission. Admission WRF was primarily defined as a 0.3 mg/dL or 50% creatinine increase from preadmission. Alternative definitions evaluated were a ≥0.5 mg/dL creatinine increase, ≥25% glomerular filtration rate decrease, and an overall change in creatinine. Predictors of admission WRF were evaluated. Outcomes evaluated were length of hospitalization, a composite of adverse in-hospital events, and the composite of death or HF readmission at 30, 90, and 365 days. Biomarkers' prognostic ability for these outcomes were evaluated in patients with admission WRF. One-hundred six patients (26%) had admission WRF. These patients had features of more severe AHF with lower blood pressure, higher BUN, and lower serum sodium concentrations at admission. Higher BNP (odds ratio [OR] per doubling 1.16-1.28, 95% confidence interval [CI] 1.00-1.55) and lower diastolic blood pressure (OR 0.97-0.98, 95% CI 0.96-0.99) were associated with a higher odds for the three definitions of admission WRF. The primary WRF definition was not associated with a longer hospitalization, but alternative WRF definitions were (1.3 to 1.6 days longer, 95% CI 1.0-2.2). WRF across definitions was not associated with a higher odds of adverse in-hospital events or a higher risk of death or HF readmission. In the subset of patients with WRF, biomarkers were not prognostic for any outcome.ConclusionsAdmission WRF is common in AHF patients and is associated with an increased length of hospitalization, but not adverse in-hospital events, death, or HF readmission. Among those with admission WRF, biomarkers did not risk stratify for adverse events.

Published
2023

12. Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation

Author

Farmakis, Dimitrios, Davison, Beth, Fountoulaki, Katerina, Liori, Sotiria, Chioncel, Ovidiu, Metra, Marco, Celutkiene, Jelena, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Edwards, Christopher, Gayat, Etienne, Novosadova, Maria, Bistola, Vasiliki, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Voors, Adriaan A., Mebazaa, Alexandre, Cotter, Gad, and Filippatos, Gerasimos

Published
2024
Full Text
View/download PDF

13. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Author

Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed, Cherney, David Z.I., DeFronzo, Ralph A., Del Prato, Stefano, Eckel, Robert H., Filippatos, Gerasimos, Fonarow, Gregg C., Fonseca, Vivian A., Garvey, W. Timothy, Giorgino, Francesco, Grant, Peter J., Green, Jennifer B., Greene, Stephen J., Groop, Per-Henrik, Grunberger, George, Jastreboff, Ania M., Jellinger, Paul S., Khunti, Kamlesh, Klein, Samuel, Kosiborod, Mikhail N., Kushner, Pamela, Leiter, Lawrence A., Lepor, Norman E., Mantzoros, Christos S., Mathieu, Chantal, Mende, Christian W., Michos, Erin D., Morales, Javier, Plutzky, Jorge, Pratley, Richard E., Ray, Kausik K., Rossing, Peter, Sattar, Naveed, Schwarz, Peter E.H., Standl, Eberhard, Steg, P. Gabriel, Tokgözoğlu, Lale, Tuomilehto, Jaakko, Umpierrez, Guillermo E., Valensi, Paul, Weir, Matthew R., Wilding, John, and Wright, Eugene E., Jr.

Published
2024
Full Text
View/download PDF

14. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk

Author

Ambrosy, Andrew P., Chang, Alex J., Davison, Beth, Voors, Adriaan, Cohen-Solal, Alain, Damasceno, Albertino, Kimmoun, Antoine, Lam, Carolyn S.P., Edwards, Christopher, Tomasoni, Daniela, Gayat, Etienne, Filippatos, Gerasimos, Saidu, Hadiza, Biegus, Jan, Celutkiene, Jelena, Ter Maaten, Jozine M., Čerlinskaitė-Bajorė, Kamilė, Sliwa, Karen, Takagi, Koji, Metra, Marco, Novosadova, Maria, Barros, Marianela, Adamo, Marianna, Pagnesi, Matteo, Arrigo, Mattia, Chioncel, Ovidiu, Diaz, Rafael, Pang, Peter S., Ponikowski, Piotr, Cotter, Gad, and Mebazaa, Alexandre

Published
2024
Full Text
View/download PDF

15. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial

Author

Arrigo, Mattia, Davison, Beth, Edwards, Christopher, Adamo, Marianna, Ambrosy, Andrew P., Barros, Marianela, Biegus, Jan, Celutkiene, Jelena, Čerlinskaitė-Bajorė, Kamilė, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Lam, Carolyn S.P., Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Voors, Adriaan A., Cotter, Gad, and Mebazaa, Alexandre

Published
2024
Full Text
View/download PDF

16. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Author

Rosano, Giuseppe, Ponikowski, Piotr, Vitale, Cristiana, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Filippatos, Gerasimos, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Ruschitzka, Frank, Kumpeson, Vasuki, Goehring, Udo-Michael, van der Meer, Peter, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

17. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

Author

Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Fonarow, Gregg C, Greene, Stephen J, Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J Stewart, Anker, Stefan D, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Heart Disease, Good Health and Well Being, Glucose, Heart Failure, Humans, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Symporters, Fragility index, Robustness, Sodium-glucose co-transporter 2 inhibitors, Cardiac failure, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsRecent trials have evaluated sodium-glucose co-transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).Methods and resultsFragility index is defined as the minimum number of patients that must be moved from the 'non-event' to the 'event' group to turn a statistically significant result to non-significant. In addition to FI, fragility quotient [(FQ); FI divided by the sample size] was calculated to assess the proportion of events that must be moved to change the significance. For statistically non-significant outcomes, reverse fragility index (RFI) and reverse fragility quotient (RFQ) were calculated. Robustness of findings after pooling data from all three trials was also assessed. A robust reduction in first HF hospitalization or cardiovascular mortality was seen with dapagliflozin (FI = 62 and FQ = 0.013), empagliflozin (FI = 50 and FQ = 0.013), and sotagliflozin (FI = 60 and FQ = 0.049). Dapagliflozin nominally improved all-cause and cardiovascular mortality, with modest FI (n = 8 and 5) and FQ (0.002 and 0.001). Empagliflozin and sotagliflozin did not demonstrate statistically significant reductions in all-cause mortality, with modest RFI (empagliflozin: RFI = 26 and RFQ = 0.007; sotagliflozin: RFI = 6 and RFQ = 0.005). A similar trend was seen with cardiovascular mortality (empagliflozin: RFI = 24 and RFQ = 0.006; sotagliflozin: RFI = 7 and RFQ = 0.006). Upon meta-analysis, the result for first HF hospitalization or cardiovascular mortality was robust (FI = 95 and FQ = 0.010). The reductions in all-cause (FI = 12 and FQ = 0.001) and cardiovascular mortality (FI = 9 and FQ = 0.001), while statistically significant, were fragile.ConclusionImprovement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality to fully understand the benefit of therapies on fatal events.

Published
2022

18. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

Author

Tomasoni, Daniela, Fonarow, Gregg C, Adamo, Marianna, Anker, Stefan D, Butler, Javed, Coats, Andrew JS, Filippatos, Gerasimos, Greene, Stephen J, McDonagh, Theresa A, Ponikowski, Piotr, Rosano, Giuseppe, Seferovic, Petar, Vaduganathan, Muthiah, Voors, Adriaan A, and Metra, Marco

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Diabetes, Cardiovascular, Heart Disease, Clinical Research, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, Metabolic and endocrine, Good Health and Well Being, Diabetes Mellitus, Type 2, Glucose, Heart Failure, Humans, Quality of Life, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume, Symporters, Heart failure with reduced ejection fraction, Sodium-glucose co-transporter 2 inhibitors, Dapagliflozin, Empagliflozin, Sotagliflozin, Medical therapy, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical practice guidelines have recommended dapagliflozin or empagliflozin in all patients with HFrEF, or sotagliflozin in those with HFrEF and concomitant diabetes, the timing and practical integration of these drugs in clinical practice is less well defined. We propose that these drugs are candidates for early, upfront administration to patients with newly diagnosed HFrEF and for patients hospitalized with HF. Growing evidence has established early benefits, with clinically meaningful reductions in clinical events that reach statistical significance within days to weeks, following dapagliflozin, empagliflozin or, in diabetic patients, sotagliflozin initiation. Secondly, although major clinical trials have tested these drugs in patients already receiving background HF therapy, secondary analyses showed that their efficacy is independent of that. Third, SGLT2 inhibitors are generally safe and well tolerated, with clinical trial data reporting minimal effects on blood pressure, glycaemia-related adverse events, and no excess in acute kidney injury. Rather, they exert renal protective effects and reduce risk of hyperkalaemia, properties that favour initiation, tolerance and persistence of renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists. This review supports the early initiation of dapagliflozin and empagliflozin (or sotagliflozin limited to patients with diabetes) to rapidly improve clinical outcome and quality of life of HFrEF patients.

Published
2022

22. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure

Author

de Koning, Marie-Sophie L. Y., Emmens, Johanna E., Romero-Hernández, Esteban, Bourgonje, Arno R., Assa, Solmaz, Figarska, Sylwia M., Cleland, John G. F., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., Metra, Marco, Filippatos, Gerasimos S., van Veldhuisen, Dirk J., Anker, Stefan D., Dickstein, Kenneth, Voors, Adriaan A., Lipsic, Erik, van Goor, Harry, and van der Harst, Pim

Published
2023
Full Text
View/download PDF

23. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial

Author

TOMASONI, DANIELA, DAVISON, BETH, ADAMO, MARIANNA, PAGNESI, MATTEO, MEBAZAA, ALEXANDRE, EDWARDS, CHRISTOPHER, ARRIGO, MATTIA, BARROS, MARIANELA, BIEGUS, JAN, ČELUTKIENĖ, JELENA, ČERLINSKAITĖ-BAJORĖ, KAMILĖ, CHIONCEL, OVIDIU, COHEN-SOLAL, ALAIN, DAMASCENO, ALBERTINO, DIAZ, RAFAEL, FILIPPATOS, GERASIMOS, GAYAT, ETIENNE, KIMMOUN, ANTOINE, LAM, CAROLYN S.P., NOVOSADOVA, MARIA, PANG, PETER S., PONIKOWSKI, PIOTR, SAIDU, HADIZA, SLIWA, KAREN, TAKAGI, KOJI, TER MAATEN, JOZINE M., VOORS, ADRIAAN, COTTER, GAD, and METRA, MARCO

Published
2024
Full Text
View/download PDF

25. Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science

Author

Agarwal, Anubha, Tromp, Jasper, Almahmeed, Wael, Angermann, Christiane, Chandramouli, Chanchal, Cho, Hyunjai, Choi, Don-Ju, Damasceno, Albertino, Filippatos, Gerasimos, Fonarow, Gregg C., Harikrishnan, Sivadasanpillai, Lund, Lars, Masoudi, Fred, Mensah, George A., Pathan, Asad, Perel, Pablo, Pinto, Fausto, Ribeiro, Antonio Luiz, Rich, Stuart, Sakata, Yasuhiko, Sliwa, Karen, Sundstrom, Johan, Wong, Renee, Yancy, Clyde, Yiu, Kelvin, Zhang, Jian, Zhang, Yuhui, Lam, Carolyn S.P., and Roth, Gregory A.

Published
2024
Full Text
View/download PDF

26. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial

Author

Čelutkienė, Jelena, Čerlinskaitė-Bajorė, Kamilė, Cotter, Gad, Edwards, Christopher, Adamo, Marianna, Arrigo, Mattia, Barros, Marianela, Biegus, Jan, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Léopold, Valentine, Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Lam, Carolyn S.P., Voors, Adriaan A., Mebazaa, Alexandre, and Davison, Beth

Published
2024
Full Text
View/download PDF

27. Performance of Different Risk Scores for the Detection of Atrial Fibrillation Among Patients With Cryptogenic Stroke

Author

Palaiodimou, Lina, Theodorou, Aikaterini, Triantafyllou, Sokratis, Dilaveris, Polychronis, Flevari, Panagiota, Giannopoulos, Georgios, Kossyvakis, Charalampos, Adreanides, Elias, Tympas, Konstantinos, Nikolopoulos, Petros, Zompola, Christina, Bakola, Eleni, Chondrogianni, Maria, Magiorkinis, Gkikas, Deftereos, Spyridon, Giannopoulos, Sotirios, Tsioufis, Konstantinos, Filippatos, Gerasimos, and Tsivgoulis, Georgios

Published
2024
Full Text
View/download PDF

28. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial

Author

BIEGUS, JAN, COTTER, GAD, DAVISON, BETH A., FREUND, YONATHAN, VOORS, ADRIAAN A., EDWARDS, CHRISTOPHER, NOVOSADOVA, MARIA, TAKAGI, KOJI, HAYRAPETYAN, Hamlet, MSHETSYAN, ANDRANIK, MAYRANUSH, DRAMBYAN, COHEN-SOLAL, ALAIN, TER MAATEN, JOZINE M., FILIPPATOS, GERASIMOS, CHIONCEL, OVIDIU, SADOUNE, MALHA, PAGNESI, MATTEO, SIMON, TABASSOME, METRA, MARCO, MANN, DOUGLAS L., MEBAZAA, ALEXANDRE, and PONIKOWSKI, PIOTR

Published
2024
Full Text
View/download PDF

29. Implementation of a cardiogenic shock team in a tertiary academic center

Author

Karamasis, Grigoris V., Polyzogopoulou, Effie, Varlamos, Charalampos, Frantzeskaki, Frantzeska, Dragona, Vassiliki-Maria, Boultadakis, Antonios, Bistola, Vasiliki, Fountoulaki, Katerina, Pappas, Christos, Kolokathis, Fotios, Pavlopoulos, Dionysios, Toumpoulis, Ioannis K., Kollias, Vasilios D., Farmakis, Dimitrios, Rallidis, Loukianos S., Angouras, Dimitrios C., Tsangaris, Iraklis, Parissis, John T., and Filippatos, Gerasimos

Published
2024
Full Text
View/download PDF

30. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper

Author

Lala, Anuradha, Hamo, Carine E., Bozkurt, Biykem, Fiuzat, Mona, Blumer, Vanessa, Bukhoff, Daniel, Butler, Javed, Costanzo, Maria Rosa, Felker, G. Michael, Filippatos, Gerasimos, Konstam, Marvin A., McMurray, John J.V., Mentz, Robert J., Metra, Marco, Psotka, Mitchell A., Solomon, Scott D., Teerlink, John, Abraham, William T., and O’Connor, Christopher M.

Published
2024
Full Text
View/download PDF

32. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

Author

Savarese, Gianluigi, Gatti, Paolo, Benson, Lina, Adamo, Marianna, Chioncel, Ovidiu, Crespo-Leiro, Maria G., Anker, Stefan D., Coats, Andrew J.S., Filippatos, Gerasimos, Lainscak, Mitja, McDonagh, Theresa, Mebazaa, Alexandre, Metra, Marco, Piepoli, Massimo F., Rosano, Giuseppe M.C., Ruschitzka, Frank, Seferovic, Petar, Volterrani, Maurizio, Maggioni, Aldo P., and Lund, Lars H.

Published
2024
Full Text
View/download PDF

33. Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure.

Author

Wettersten, Nicholas, Horiuchi, Yu, van Veldhuisen, Dirk, Ix, Joachim, Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael, Cannon, Chad, Müeller, Gerhard, Birkhahn, Robert, Taub, Pam, Vilke, Gary, Duff, Stephen, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Maisel, Alan, and Murray, Patrick

Subjects
Acute heart failure, B-type natriuretic peptide, Congestion, Kidney function, Prognosis, Acute Disease, Aged, Biomarkers, Heart Failure, Humans, Kidney, Male, Natriuretic Peptide, Brain, Prognosis
Abstract

AIMS: Improving renal function (IRF) is paradoxically associated with worse outcomes in acute heart failure (AHF), but outcomes may differ based on response to decongestion. We explored if the relationship of IRF with mortality in hospitalized AHF patients differs based on successful decongestion. METHODS AND RESULTS: We evaluated 760 AHF patients from AKINESIS for the relationship between IRF, change in B-type natriuretic peptide (BNP), and 1-year mortality. IRF was defined as a ≥20% increase in estimated glomerular filtration rate (eGFR) relative to admission. Adequate decongestion was defined as a ≥40% decrease in last measured BNP relative to admission. IRF occurred in 22% of patients who had a mean age of 69 years, 58% were men, 72% were white, and median admission eGFR was 49 mL/min/1.73 m2 . IRF patients had more severe heart failure reflected by lower admission eGFR, higher blood urea nitrogen, lower systolic blood pressure, lower sodium, and higher use of inotropes. IRF patients had higher 1-year mortality (25%) than non-IRF patients (15%) (P

Published
2021

34. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

Author

Gerhardt, Teresa, Gerhardt, Louisa M S, Ouwerkerk, Wouter, Roth, Gregory A, Dickstein, Kenneth, Collins, Sean P, Cleland, John G F, Dahlstrom, Ulf, Tay, Wan Ting, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Lam, Carolyn S P, Tromp, Jasper, and Angermann, Christiane E

Published
2023
Full Text
View/download PDF

35. Cardiorenal multimorbidity in hospitalized cardiology patients: The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study

Author

Leontsinis, Ioannis, Farmakis, Dimitrios, Avramidis, Dimitrios, Andrikou, Eirini, Valatsou, Angeliki, Gartzonikas, Elias, Doundoulakis, Ioannis, Zarifis, Ioannis, Karpouzis, Ioannis, Kafkala, Kristalenia, Kouvelas, Nikos, Kourek, Christos, Koufou, Eleni, Kochiadakis, George, Kifnidis, Konstantinos, Liori, Sotiria, Manolis, George, Marketou, Maria, Moschos, Nikitas, Bampatsias, Dimitrios, Bibis, George, Bonou, Maria, Naka, Aikaterini, Davlouros, Periklis, Ntalakouras, Ioannis, Papakonstantinou, Panteleimon Ε., Pappa, Evgenia, Patsilinakos, Sotirios, Plaitis, Aristeidis, Sideris, Antonios, Sideris, Skevos, Skoularigis, John, Stamatelopoulos, Kimon, Stefanou, Garyfallia, Tziakas, Dimitrios, Chatzieleftheriou, Christos, Chrysochoou, Christina, Filippatos, Gerasimos, and Tsioufis, Costas

Published
2023
Full Text
View/download PDF

37. Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial

Author

Wilkoff, Bruce L, Filippatos, Gerasimos, Leclercq, Christophe, Gold, Michael R, Hersi, Ahmad S, Kusano, Kengo, Mullens, Wilfried, Felker, G Michael, Kantipudi, Charan, El-Chami, Mikhael F, Essebag, Vidal, Pierre, Bertrand, Philippon, Francois, Perez-Gil, Francisco, Chung, Eugene S, Sotomonte, Juan, Tung, Stanley, Singh, Balbir, Bozorgnia, Babak, Goel, Satish, Ebert, Hans Holger, Varma, Niraj, Quan, Kara J, Salerno, Fiorella, Gerritse, Bart, van Wel, Janelle, Schaber, Daniel E, Fagan, Dedra H, and Birnie, David

Published
2023
Full Text
View/download PDF

38. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry

Author

Tromp, Jasper, Ezekowitz, Justin A., Ouwerkerk, Wouter, Chandramouli, Chanchal, Yiu, Kai Hang, Angermann, Christiane E., Dahlstrom, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V., Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Collins, Sean P., Filippatos, Gerasimos, Cleland, John G.F., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

39. Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results

Author

Khan, Muhammad Shahzeb, Shahid, Izza, Asad, Nava, Greene, Stephen J, Khan, Safi U, Doukky, Rami, Metra, Marco, Anker, Stefan D, Filippatos, Gerasimos S, Fonarow, Gregg C, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Heart Disease, Clinical Trials and Supportive Activities, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Cross-Sectional Studies, Heart Failure, Humans, Randomized Controlled Trials as Topic, Heart failure, Clinical trials, Discontinuation, Non-publication, Enrolment, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsDiscontinuation or non-publication of trials may hinder scientific progress and violates the commitment made to research participants. We sought to identify the prevalence of discontinuation and non-publication of heart failure (HF) clinical trials.Methods and resultsWe conducted a cross-sectional search of ClinicalTrials.gov to identify all completed and discontinued HF clinical trials. We limited our search to only include trials that were completed by 31 December 2017. Trials were investigated to identify reasons for discontinuation. Informative termination was defined as trial termination due to safety or efficacy concerns. Data pertaining to the trial phase, funding, intervention, enrolment, and trial completion date were extracted for each trial. A total of 572 trials were included. Of these, 21% (n = 118) were discontinued before completion. Patient accrual was the most frequently cited reason (n = 42; 36%) for trial discontinuation, followed by informative termination (n = 16; 14%) and funding (n = 14; 12%). Overall, 24 780 patients were enrolled in trials that were terminated. Of trials that were completed and not terminated, nearly one-third (n = 131/454; 29%) were not published. Seventy-nine (24%) trials were published within 12 months, 192 (59%) within 24 months, and 252 (78%) trials within 36 months.ConclusionsDiscontinuation and non-publication of HF trials is common. This raises ethical concerns towards participants who volunteer for research and are exposed to potential risks, inconvenience, and discomfort without furthering scientific progress.

Published
2021

40. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Author

Anker, Stefan D., Butler, Javed, Usman, Muhammad Shariq, Filippatos, Gerasimos, Ferreira, João Pedro, Bocchi, Edimar, Böhm, Michael, Rocca, Hans Pieter Brunner-La, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L., González-Juanatey, José R., Merkely, Bela, Nicholls, Stephen J., Perrone, Sergio V., Piña, Ileana L., Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Iwata, Tomoko, Schnee, Janet M., Brueckmann, Martina, Pocock, Stuart J., and Zannad, Faiez

Published
2022
Full Text
View/download PDF

43. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations

Author

Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Anker, Stefan D., Bakris, George L., Bhatt, Deepak L., Filippatos, Gerasimos, Fonarow, Gregg C., Greene, Stephen J., Januzzi, James L., Jr, Khan, Muhammad Shahzeb, Kosiborod, Mikhail N., McGuire, Darren K., Piña, Ileana L., Rosenstock, Julio, Vaduganathan, Muthiah, Verma, Subodh, Zieroth, Shelley, and Butler, Javed

Published
2023
Full Text
View/download PDF

45. Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure

Author

Faselis, Charles, Arundel, Cherinne, Patel, Samir, Lam, Phillip H, Gottlieb, Stephen S, Zile, Michael R, Deedwania, Prakash, Filippatos, Gerasimos, Sheriff, Helen M, Zeng, Qing, Morgan, Charity J, Wopperer, Samuel, Nguyen, Tran, Allman, Richard M, Fonarow, Gregg C, and Ahmed, Ali

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Cardiovascular, Clinical Research, Heart Disease, Aged, Aged, 80 and over, Cohort Studies, Female, Heart Failure, Humans, Male, Sodium Potassium Chloride Symporter Inhibitors, Time Factors, Treatment Outcome, heart failure, loop diuretics, outcomes, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundHeart failure (HF) is a major source of morbidity and mortality. Fluid retention and shortness of breath are its cardinal manifestations for which loop diuretics are used. Although their usefulness is well accepted, less is known about their role in improving clinical outcomes.ObjectivesThe purpose of this study was to determine the relationship between loop diuretics and clinical outcomes in patients with HF.MethodsOf the 25,345 older patients hospitalized for HF in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 9,866 (39%) received no pre-admission diuretics. The study excluded 1,083 patients receiving dialysis and 847 discharged on thiazide diuretics. Of the remaining 7,936 patients, 5,568 (70%) were prescribed loop diuretics at discharge. Using propensity scores for receipt of loop diuretics estimated for each of the 7,936 patients, a matched cohort of 2,191 pairs of patients was assembled balanced on 74 baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes were estimated in the matched cohort.ResultsMatched patients (n = 4,382) had a mean age of 78 years, 54% were women, and 11% were African American. The 30-day all-cause mortality occurred in 4.9% (107 of 2,191) and 6.6% (144 of 2,191) of patients in the loop diuretic and no loop diuretic groups, respectively (HR when the use of loop diuretics was compared with nonuse: 0.73; 95% CI: 0.57 to 0.94; p = 0.016). Patients in the loop diuretic group had a significantly lower risk of 30-day HF readmission (HR: 0.79; 95% CI: 0.63 to 0.99; p = 0.037) but not of 30-day all-cause readmission (HR: 0.89; 95% CI: 0.79 to 1.01; p = 0.081). None of the associations was statistically significant during 60 days of follow-up.ConclusionsHospitalized older patients not taking diuretics prior to hospitalization for HF decompensation who received a discharge prescription for loop diuretics had significantly better 30-day clinical outcomes than those not discharged on loop diuretics. These findings provide new information about short-term clinical benefits associated with loop diuretic use in HF.

Published
2020

46. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Author

Anker, Stefan D, Butler, Javed, Khan, Muhammad Shahzeb, Abraham, William T, Bauersachs, Johann, Bocchi, Edimar, Bozkurt, Biykem, Braunwald, Eugene, Chopra, Vijay K, Cleland, John G, Ezekowitz, Justin, Filippatos, Gerasimos, Friede, Tim, Hernandez, Adrian F, Lam, Carolyn SP, Lindenfeld, JoAnn, McMurray, John JV, Mehra, Mandeep, Metra, Marco, Packer, Milton, Pieske, Burkert, Pocock, Stuart J, Ponikowski, Piotr, Rosano, Giuseppe MC, Teerlink, John R, Tsutsui, Hiroyuki, Van Veldhuisen, Dirk J, Verma, Subodh, Voors, Adriaan A, Wittes, Janet, Zannad, Faiez, Zhang, Jian, Seferovic, Petar, and Coats, Andrew JS

Subjects
Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Prevention, Good Health and Well Being, Betacoronavirus, COVID-19, Clinical Trials as Topic, Coronavirus Infections, Europe, Heart Failure, Humans, Informed Consent, Pandemics, Patient Selection, Pneumonia, Viral, Research Design, SARS-CoV-2, Heart failure, Clinical trials, Coronavirus, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. As physicians and clinical trialists, it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial. The social contract with our patients demands no less. Many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this COVID-19 crisis. However, international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations, thereby enhancing the safety of participants and the integrity of the trial. Accordingly, the Heart Failure Association of the European Society of Cardiology on 21 and 22 March 2020 conducted web-based meetings with expert clinical trialists in Europe, North America, South America, Australia, and Asia. The main objectives of this Expert Position Paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome, with some practical examples. While this panel of experts are focused on heart failure clinical trials, these discussions and recommendations may apply to clinical trials in other therapeutic areas.

Published
2020

47. Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial

Author

Biegus, Jan, Demissei, Biniyam, Postmus, Douwe, Cotter, Gad, Davison, Beth A, Felker, G Michael, Filippatos, Gerasimos, Gimpelewicz, Claudio, Greenberg, Barry, Metra, Marco, Severin, Thomas, Teerlink, John R, Voors, Adriaan A, and Ponikowski, Piotr

Subjects
Cardiovascular, Acute Disease, Aged, Aged, 80 and over, Bilirubin, Creatinine, Female, Heart Failure, Humans, Kidney Diseases, Liver Diseases, Male, Middle Aged, Prognosis, Severity of Illness Index, Acute heart failure, Liver dysfunction, Kidney dysfunction, MELD-XI score, Cardiorespiratory Medicine and Haematology
Abstract

AimsEpisodes of acute heart failure (AHF) may lead to end-organ dysfunction. In this post hoc analysis of the Relaxin in Acute Heart Failure trial, we used the MELD-XI (Model of End-Stage Liver Dysfunction) score to examine hepatorenal dysfunction in patients with AHF.Methods and resultsOn admission, the MELD-XI score was elevated (abnormal) in 918 (82%) patients, with 638 (57%) having isolated renal dysfunction (creatinine > 1 mg/dL), 73 (6.5%) isolated liver dysfunction (bilirubin > 1 mg/dL), and 207 (18.5%) coexisting dysfunction of the kidneys and the liver (both creatinine and bilirubin > 1 mg/dL). The percentage of patients with elevated MELD-XI score remained constant through a 60 day follow-up, as we observed a gradual decrease of liver dysfunction prevalence, counterbalanced by an increase in renal dysfunction. Serelaxin treatment was associated with a lower MELD-XI score on Day 2 and Day 5 (both P

Published
2019

48. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Author

Tsutsui, HIROYUKI, ALBERT, NANCY M., COATS, ANDREW J.S., ANKER, STEFAN D., BAYES-GENIS, ANTONI, BUTLER, JAVED, CHIONCEL, OVIDIU, DEFILIPPI, CHRISTOPHER R., DRAZNER, MARK H., FELKER, G. MICHAEL, FILIPPATOS, GERASIMOS, FIUZAT, MONA, IDE, TOMOMI, JANUZZI, JAMES L., Jr, KINUGAWA, KOICHIRO, KUWAHARA, KOICHIRO, MATSUE, YUYA, MENTZ, ROBERT J., METRA, MARCO, PANDEY, AMBARISH, ROSANO, GIUSEPPE, SAITO, YOSHIHIKO, SAKATA, YASUSHI, SATO, NAOKI, SEFEROVIC, PETAR M., TEERLINK, JOHN, YAMAMOTO, KAZUHIRO, and YOSHIMURA, MICHIHIRO

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results